These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 34841193)
21. Safety Profile of Recommended Vaccinations in Adolescents: Data from Surveillance of Adverse Events Following Immunization in Puglia (Italy), 2016-2020. Di Lorenzo A; Bianchi FP; Martinelli A; Lattanzio S; Carbonara A; Diella G; Tafuri S; Stefanizzi P Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835232 [TBL] [Abstract][Full Text] [Related]
22. Adverse Events Following Immunization- The Known Unknowns and Black Box : Based on 10th Dr. I. C. Verma Excellence Award for Young Pediatricians Delivered as Oration on 9th Oct. 2022. Das MK Indian J Pediatr; 2023 Aug; 90(8):817-825. PubMed ID: 37233889 [TBL] [Abstract][Full Text] [Related]
23. Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data. Bellavite P; Donzelli A F1000Res; 2020; 9():1176. PubMed ID: 33335717 [TBL] [Abstract][Full Text] [Related]
24. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone "beep" in a Cameroon health district: a randomized field trial. Tsafack M; Ateudjieu J Pan Afr Med J; 2015; 22():351. PubMed ID: 26985269 [TBL] [Abstract][Full Text] [Related]
25. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea. Jeon M; Kim J; Oh CE; Lee JY Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204 [TBL] [Abstract][Full Text] [Related]
26. Profile of adverse events following immunization with measles rubella vaccine at a tertiary care hospital in East Delhi, India. Bhowmik E; Singh A; Sachan R Ther Adv Vaccines Immunother; 2020; 8():2515135520940131. PubMed ID: 32685913 [TBL] [Abstract][Full Text] [Related]
27. Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study. Velhal GD; Kamath YV; Agrawal AS; Vora DS; Dwivedi VR Indian J Community Med; 2022; 47(4):613-617. PubMed ID: 36742958 [TBL] [Abstract][Full Text] [Related]
28. Adverse Event Following Immunization (AEFI) in Children: An Analysis of Reporting in VigiAccess. Pandey D; Mehta G; Sachdeva M; Tripathi R Drug Res (Stuttg); 2022 Oct; 72(8):435-440. PubMed ID: 35724674 [TBL] [Abstract][Full Text] [Related]
29. A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis. Kaur U; K L A; Chauhan M; Joshi A; Das A; Kansal S; Jaisawal V; Patwardhan K; Chakrabarti SS Drug Saf; 2022 Oct; 45(10):1099-1109. PubMed ID: 36030299 [TBL] [Abstract][Full Text] [Related]
30. Adverse Events Following Measles-Mumps-Rubella-Varicella Vaccination and the Case of Seizures: A Post Marketing Active Surveillance in Puglia Italian Region, 2017-2018. Stefanizzi P; Stella P; Ancona D; Malcangi KN; Bianchi FP; De Nitto S; Ferorelli D; Germinario CA; Tafuri S Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31591347 [TBL] [Abstract][Full Text] [Related]
31. A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study. Zeitoun A; Hallit S; Chehade S; Ibrahim A; Helali M; Allam C; Karam R J Pharm Policy Pract; 2023 Feb; 16(1):24. PubMed ID: 36810279 [TBL] [Abstract][Full Text] [Related]
32. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature. Duijster JW; Lieber T; Pacelli S; Van Balveren L; Ruijs LS; Raethke M; Kant A; Van Hunsel F Front Immunol; 2023; 14():1078736. PubMed ID: 36793715 [TBL] [Abstract][Full Text] [Related]
34. Using Population-Based Structures to Actively Monitor AEFIs during a Mass Immunization Campaign-A Case of Measles-Rubella and Polio Vaccines. Kajungu D; Nambasa V; Muhoozi M; Tusabe J; Kampmann B; Todd J Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835224 [TBL] [Abstract][Full Text] [Related]
35. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. Kaur U; Ojha B; Pathak BK; Singh A; Giri KR; Singh A; Das A; Misra A; Yadav AK; Kansal S; Chakrabarti SS EClinicalMedicine; 2021 Aug; 38():101038. PubMed ID: 34505032 [TBL] [Abstract][Full Text] [Related]
36. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X Front Immunol; 2021; 12():669010. PubMed ID: 34093567 [TBL] [Abstract][Full Text] [Related]
37. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign. Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655 [TBL] [Abstract][Full Text] [Related]
38. Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy). Stefanizzi P; Ferorelli D; Scazzi FL; Di Lorenzo A; Martinelli A; Trinchera C; Moscara L; Miniello E; Di Bona D; Tafuri S Front Immunol; 2023; 14():1074246. PubMed ID: 36923411 [TBL] [Abstract][Full Text] [Related]